| Name | Title | Contact Details |
|---|
Need an easy solution to manage your construction business? All your project data in one place. Take the best of a CRM, project management and invoicing software. Thats Knowify.
A school information system based on a single, fully integrated database, providing a platform for the future, all delivered with exceptional service.
ACCES I/O Products , Inc. is a San Diego, CA-based company in the Software and Internet sector.
Cuurio is an index of startups and an ideation platform that connects brands and agencies with emerging technology to create breakthrough partnerships. Since launching in beta this past November, Cuurio has grown to work with a number of Fortune 500 brands to support CMOs, innovation teams, brand managers, as well as research and development efforts. Built to foster excitement for and clarity around startup integrations in a flooded digital / app market, Cuurio's algorithmic curation provides vetted opportunities for brand customers – think of Cuurio as a marketplace bringing together innovation and opportunity! The startups indexed on the platform are vetted by Cuurio and brand-facing profiles are created for each startup. These profiles provide: quick context, real metrics (not shared publicly), case stories, and direct connection to startup founders ready to find ways to partner with brands. Cuurio sources startups from deep relationships in the global startup community as well as via a broad network of venture capital funds and accelerators for ongoing access to a vast pipeline of the best B2C innovation.
Immunome is a biotechnology company with a growing pipeline of cancer immunotherapies fueled by the human immune system. Our unique and powerful immunotherapy discovery engine leverages “most highly educated” immune systems from patients who have already learned how to fight off their disease. This proprietary technology platform enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens. We then employ a battery of high-content screening technologies to identify specific and high-affinity antibodies that offer significant therapeutic potential to change the way we treat cancer.